These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 37540461)
1. Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. de Oliveira Kocerginsky P; Dos Santos Soares PH; Lyra HFS; Cadena PG; de Lima-Neto RG; Pontes-Filho NT; Lima-Filho JVM; Costa-Júnior SD; Neves RP; Cavalcanti IMF; Santos-Magalhães NS Braz J Microbiol; 2023 Sep; 54(3):1513-1521. PubMed ID: 37540461 [TBL] [Abstract][Full Text] [Related]
2. Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice. Khan MA; Owais M J Drug Target; 2005 Aug; 13(7):423-9. PubMed ID: 16308211 [TBL] [Abstract][Full Text] [Related]
3. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Le Conte P; Joly V; Saint-Julien L; Gillardin JM; Carbon C; Yeni P Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577 [TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy of pH-sensitive nystatin liposomes against Cryptococcus neoformans in murine model. Nasti TH; Khan MA; Owais M J Antimicrob Chemother; 2006 Feb; 57(2):349-52. PubMed ID: 16368700 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Schwarz P; Dromer F; Lortholary O; Dannaoui E Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675 [TBL] [Abstract][Full Text] [Related]
6. New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans Lu RY; Ni TJ; Wu J; Yan L; Lv QZ; Li LP; Zhang DZ; Jiang YY Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791946 [TBL] [Abstract][Full Text] [Related]
7. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. Barchiesi F; Schimizzi AM; Caselli F; Giannini D; Camiletti V; Fileni B; Giacometti A; Di Francesco LF; Scalise G J Antimicrob Chemother; 2001 Dec; 48(6):769-73. PubMed ID: 11733459 [TBL] [Abstract][Full Text] [Related]
8. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099 [TBL] [Abstract][Full Text] [Related]
10. Immune stimulating and therapeutic potential of tuftsin-incorporated nystatin liposomes against Cryptococcus neoformans in leukopenic BALB/C mice. Khan MA; Aljarbou A; Khan A; Owais M FEMS Immunol Med Microbiol; 2012 Oct; 66(1):88-97. PubMed ID: 22612788 [TBL] [Abstract][Full Text] [Related]
11. Antifungal activity of the naphthoquinone beta-lapachone against disseminated infection with Cryptococcus neoformans var. neoformans in dexamethasone-immunosuppressed Swiss mice. Medeiros CS; Pontes-Filho NT; Camara CA; Lima-Filho JV; Oliveira PC; Lemos SA; Leal AF; Brandão JO; Neves RP Braz J Med Biol Res; 2010 Apr; 43(4):345-9. PubMed ID: 20209378 [TBL] [Abstract][Full Text] [Related]
12. Brilacidin, a novel antifungal agent against Diehl C; Pinzan CF; de Castro PA; Delbaje E; García Carnero LC; Sánchez-León E; Bhalla K; Kronstad JW; Kim D-g; Doering TL; Alkhazraji S; Mishra NN; Ibrahim AS; Yoshimura M; Vega Isuhuaylas LA; Pham LTK; Yashiroda Y; Boone C; Dos Reis TF; Goldman GH mBio; 2024 Jul; 15(7):e0103124. PubMed ID: 38916308 [TBL] [Abstract][Full Text] [Related]
13. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil. Moreira IMB; Cortez ACA; de Souza ÉS; Pinheiro SB; de Souza Oliveira JG; Sadahiro A; Cruz KS; Matsuura ABJ; Melhem MSC; Frickmann H; de Souza JVB Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35084497 [TBL] [Abstract][Full Text] [Related]
14. Formulation and Evaluation of Novel Hybridized Nanovesicles for Enhancing Buccal Delivery of Ciclopirox Olamine. AbouSamra MM; Salama AH; Awad GEA; Mansy SS AAPS PharmSciTech; 2020 Oct; 21(7):283. PubMed ID: 33051708 [TBL] [Abstract][Full Text] [Related]
15. Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model. Khan MA; Jabeen R; Nasti TH; Mohammad O J Antimicrob Chemother; 2005 Feb; 55(2):223-8. PubMed ID: 15590713 [TBL] [Abstract][Full Text] [Related]
16. Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. Furukawa K; Sasaki H; Pollard RB; Suzuki F J Antimicrob Chemother; 2000 Sep; 46(3):443-50. PubMed ID: 10980172 [TBL] [Abstract][Full Text] [Related]
17. Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal. Karimunnisa S; Atmaram P Drug Dev Ind Pharm; 2013 Sep; 39(9):1328-37. PubMed ID: 22866766 [TBL] [Abstract][Full Text] [Related]
18. Ciclopirox olamine: an antifungal alternative against cryptococcosis. Oliveira PC; Medeiros CS; Macêdo DP; Andrade SL; Correia MT; Mesquita SD; Lima-Neto RG; Neves RP Lett Appl Microbiol; 2010 Nov; 51(5):485-9. PubMed ID: 21039663 [TBL] [Abstract][Full Text] [Related]